Literature DB >> 23809254

Primary bone marrow mesenchymal stromal cells rescue the axonal phenotype of Twitcher mice.

Catarina Oliveira Miranda1, Carla Andreia Teixeira, Vera Filipe Sousa, Telma Emanuela Santos, Márcia Almeida Liz, Ana Maio Marques, Perpétua Pinto-do-Ó, Mónica Mendes Sousa.   

Abstract

Krabbe's disease (KD) is a demyelinating disorder caused by the deficiency of lysosomal galactocerebrosidase (GALC), affecting both the central (CNS) and the peripheral nervous system (PNS). A current therapy, hematopoietic stem cell transplantation (HSCT), is ineffective at correcting the PNS pathology. We have previously shown that systemic delivery of immortalized bone marrow-derived murine mesenchymal stromal cells (BM-MSCs) diminishes the neuropathology of transplanted Twitcher mice, a murine model of KD. In this study, to move one step closer to clinical application, the effectiveness of a systematic delivery of primary BM-MSCs to promote recovery of the Twitcher PNS was assessed. Primary BM-MSCs grafted to the Twitcher sciatic nerve led to increased GALC activity that was not correlated to decreased psychosine (the toxic GALC substrate) accumulation. Nevertheless, BM-MSC transplantation rescued the axonal phenotype of Twitcher mice in the sciatic nerve, with an increased density of both myelinated and unmyelinated axons in transplanted animals. Whereas no increase in myelination was observed, upon transplantation an increased proliferation of Schwann cell precursors occurred. Supporting these findings, in vitro, BM-MSCs promoted neurite outgrowth of Twitcher sensory neurons and proliferation of Twitcher Schwann cells. Moreover, BM-MSCs expressed nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) and promoted increased BDNF synthesis by neighboring Schwann cells. Besides their action in neurons and glia, BM-MSCs led to macrophage activation in Twitcher sciatic nerves. In summary, primary BM-MSCs diminish the neuropathology of Twitcher sciatic nerves by coordinately affecting neurons, glia, and macrophages.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23809254     DOI: 10.3727/096368913X669752

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  5 in total

1.  Early axonal loss accompanied by impaired endocytosis, abnormal axonal transport, and decreased microtubule stability occur in the model of Krabbe's disease.

Authors:  Carla Andreia Teixeira; Catarina Oliveira Miranda; Vera Filipe Sousa; Telma Emanuela Santos; Ana Rita Malheiro; Melani Solomon; Gustavo H Maegawa; Pedro Brites; Mónica Mendes Sousa
Journal:  Neurobiol Dis       Date:  2014-03-06       Impact factor: 5.996

2.  Repeated Mesenchymal Stromal Cell Treatment Sustainably Alleviates Machado-Joseph Disease.

Authors:  Catarina Oliveira Miranda; Adriana Marcelo; Teresa Pereira Silva; João Barata; Ana Vasconcelos-Ferreira; Dina Pereira; Clévio Nóbrega; Sónia Duarte; Inês Barros; Joana Alves; José Sereno; Lorena Itatí Petrella; João Castelhano; Vitor Hugo Paiva; Paulo Rodrigues-Santos; Vera Alves; Isabel Nunes-Correia; Rui Jorge Nobre; Célia Gomes; Miguel Castelo-Branco; Luís Pereira de Almeida
Journal:  Mol Ther       Date:  2018-07-12       Impact factor: 11.454

Review 3.  Experimental therapies in the murine model of globoid cell leukodystrophy.

Authors:  Yedda Li; Mark S Sands
Journal:  Pediatr Neurol       Date:  2014-08-08       Impact factor: 3.372

Review 4.  Stem Cell Therapy for the Central Nervous System in Lysosomal Storage Diseases.

Authors:  Faez Siddiqi; John H Wolfe
Journal:  Hum Gene Ther       Date:  2016-07-13       Impact factor: 5.695

5.  Lysosomal Re-acidification Prevents Lysosphingolipid-Induced Lysosomal Impairment and Cellular Toxicity.

Authors:  Christopher J Folts; Nicole Scott-Hewitt; Christoph Pröschel; Margot Mayer-Pröschel; Mark Noble
Journal:  PLoS Biol       Date:  2016-12-15       Impact factor: 8.029

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.